Agenus Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness Wire • 1 day ago
Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum...
Share to Feed
Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results...
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.
Latest Ratings for AGEN...
Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL...
Down 75%. Is Agenus Stock a Buy on the Dip...
Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock...
Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...
StockNews.com upgraded shares of Agenus (NASDAQ:AGEN Free Report) from a sell rating to a hold rating in a research report released on Sunday morning. Several other analysts have also issued...
Agenus (NASDAQ:AGEN Free Report) had its price objective cut by B. Riley from $6.00 to $5.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the...
Related Stocks: NAS:AGEN...